-
2022-500747-21-00
4
2025-02-27
Geographic Atrophy
-
2024-515661-34-00
6
2025-02-27
Transthyretin cardiac amyloidosis
-
2023-510292-65-00
5
2025-02-25
chronic graft-versus-host disease
-
2024-514281-39-00
5
2025-02-14
Metastatic Squamous Non-small Cell Lung Cancer Whose Tumors Express PD
-
2024-515008-38-00
5
2025-02-14
Metastatic Non-squamous Non-small Cell Lung Cancer Whose Tumors Expres
-
2024-512901-22-00
5
2025-02-10
Acute Heart Failure
-
2024-512960-75-00
5
2025-02-04
Resectable Non-small cell lung cancer
-
2024-513803-15-00
6
2025-01-30
Acute myocarditis
-
2023-505868-11-00
5
2025-01-17
CHRONIC RENAL DISEASE
-
2024-512161-14-00
3
2025-01-14
Breast Cancer
-
2023-509883-89-00
5
2025-01-09
Epidermal growth factor receptor (EGFR) mutation-positive, locally adv
-
2024-513441-36-00
4
2024-11-27
MMRp/ MSS colon cancer
-
2024-512895-36-00
5
2024-11-25
Non Alcoholic Steatohepatitis (NASH)
-
2024-515381-14-00
6
2024-11-20
heartburn and or reflux
-
2024-513098-31-00
4
2024-11-14
Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma
-
2024-512338-13-00
3
2024-11-11
Metastatic Castration-Resistant Prostate Cancer
-
2023-509912-27-00
5
2024-11-07
Metabolic Dysfunction-Associated Steatotic Liver Disease(MASH) / Nonal
-
2023-505242-25-00
4
2024-11-05
High-Risk Monoclonal Gammopathy of Undetermined Significance;
Non-Hig
-
2022-502972-22-00
5
2024-10-31
Clostridioides difficile infection.
-
2023-509340-10-00
5
2024-10-29
Patients with HLA-A2 positive phenotype and metastatic Non-Small Cell
-
2024-511319-91-00
5
2024-10-23
Advanced non-small cell lung cancer with HER2 (ERBB2) mutation
-
2024-512194-27-01
6
2024-10-21
Patients receiving oral anticoagulant therapy who are scheduled for el
-
2023-508581-15-00
5
2024-10-08
Heart condition
-
2023-508338-33-00
5
2024-10-01
Chronic Inflammatory Demyelinating Polyneuropathy